How relevant are social costs in economic evaluations? The case of Alzheimer’s disease

Abstract

Background

The main objective of this study was to analyse how the inclusion (exclusion) of social costs can alter the results and conclusions of economic evaluations in the field of Alzheimer’s disease interventions.

Methods

We designed a systematic review that included economic evaluations in Alzheimer’s disease. The search strategy was launched in 2000 and ran until November 2018. The inclusion criteria were: being an original study published in a scientific journal, being an economic evaluation of any intervention related to Alzheimer’s disease, including social costs (informal care costs and/or productivity losses), being written in English, using QALYs as an outcome for the incremental cost–utility analysis, and separating the results according to the perspective applied.

Results

It was finally included 27 studies and 55 economic evaluations. Around 11% of economic evaluations changed their main conclusions. More precisely, three of them concluded that the new intervention became cost-effective when the societal perspective was considered, whereas when using just the health care payer perspective, the new intervention did not result in a cost–utility ratio below the threshold considered. Nevertheless, the inclusion of social cost can also influence the results, as 37% of the economic evaluations included became the dominant strategy after including social costs when they were already cost-effective in the health care perspective.

Conclusions

Social costs can substantially modify the results of the economic evaluations. Therefore, taking into account social costs in diseases such as Alzheimer’s can be a key element in making decisions about public financing and pricing of health interventions.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2

References

  1. 1.

    Drummond, M.: Twenty years of using economic evaluations for reimbursement decisions. What have we achieved? CHE Research Paper 75. Centre for Health Economics, University of York, UK (2002)

  2. 2.

    Paris, V., Belloni, A.: Value in pharmaceutical pricing. OECD Health Working Papers, No. 63, OECD (2013)

  3. 3.

    Oliva, J., Antoñanzas. F., Rivero-Arias, O.: Evaluación económica y la toma de decisiones en salud. El papel de la evaluación económica en la adopción y difusión de tecnologías sanitarias. Informe SESPAS 2008. Gac Sanit. 22(Suppl 1), 137–142 (2008)

    PubMed  Article  Google Scholar 

  4. 4.

    Joo, H., George, M.G., Fang, J., et al.: A literature review of indirect costs associated with stroke. J. Stroke Cerebrovasc. Dis. 23(7), 1753–1763 (2014)

    PubMed  PubMed Central  Article  Google Scholar 

  5. 5.

    Pares-Badell, O., Barbaglia, G., Jerinic, P., et al.: Cost of disorders of the brain in Spain. PLoS One 9(8), e105471 (2014)

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  6. 6.

    Leal, J., Luengo-Fernandez, R., Gray, A., et al.: Economic burden of cardiovascular diseases in the enlarged European Union. Eur. Heart J. 27, 1610–1619 (2006)

    PubMed  Article  Google Scholar 

  7. 7.

    Luengo-Fernandez, R., Leal, J., Gray, A.M.: Cost of dementia in the pre-enlargement countries of the European Union. J. Alzheimers Dis. 27(1), 187–197 (2011)

    PubMed  Article  Google Scholar 

  8. 8.

    Luengo-Fernandez, R., Leal, J., Gray, A.M., et al.: Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 14, 1165–1174 (2013)

    PubMed  Article  Google Scholar 

  9. 9.

    Oliva-Moreno, J., Trapero-Bertran, M., Peña-Longobardo, L.M., et al.: The valuation of informal care in cost-of-illness studies: a systematic review. Pharmacoeconomics. 35(3), 331–345 (2017)

    PubMed  Article  Google Scholar 

  10. 10.

    López-Bastida, J., Oliva-Moreno, J., Linertová, R., et al.: Social/economic costs and health-related quality of life in patients with rare diseases in Europe. Eur. J. Health Econ. 17(Suppl 1), 1–5 (2016)

    PubMed  Article  Google Scholar 

  11. 11.

    Chari, A.V., Engberg, J., Ray, K.N., et al.: The opportunity costs of informal elder-care in the United States: new estimates from the American time use survey. Health Serv. Res. 50(3), 871–882 (2015)

    PubMed  Article  Google Scholar 

  12. 12.

    Oliva-Moreno, J.: Loss of labour productivity caused by disease and health problems: what is the magnitude of its effect on Spain’s economy? Eur. J. Health Econ. 13(5), 605–614 (2012)

    PubMed  Article  Google Scholar 

  13. 13.

    Peña, L.M., Aranda, I., Oliva-Moreno, J., et al.: Pérdidas laborales ocasionadas por los fallecimientos prematuros. un análisis del periodo 2005–2009. Revista Española de Salud Pública. 89(1), 39–50 (2015)

    Article  Google Scholar 

  14. 14.

    Arno, P.S., Levine, C., Memmott, M.M.: The economic value of informal caregiving. Health Aff. (Millwood). 18(2), 182–188 (1999)

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Peña-Longobardo, L., Aranda-Reneo, I., Oliva, J., et al.: Evaluación de las pérdidas laborales provocadas enfermedades y lesiones en España en el año 2009. Revista de Evaluación de Programas y Políticas Públicas. 6, 66–85 (2016)

    Article  Google Scholar 

  16. 16.

    Oliva-Moreno, J., Peña-Longobardo, L.M., Vilaplana-Prieto, C.: An estimation of the value of informal care provided to dependent people in Spain. Appl. Health Econ. Health Policy. 13(2), 223–231 (2015)

    PubMed  Article  Google Scholar 

  17. 17.

    Hollander, M.J., Liu, G., Chappell, N.L.: Who cares and how much? The imputed economic contribution to the Canadian healthcare system of middle-aged and older unpaid caregivers providing care to the elderly. Healthc. Q. 12(2), 42–49 (2009)

    PubMed  Article  Google Scholar 

  18. 18.

    Paraponaris, A., Davin, B., Verger, P.: Formal and informal care for disabled elderly living in the community: an appraisal of French care composition and costs. Eur. J. Health Econ. 13(3), 327–336 (2012)

    PubMed  Article  Google Scholar 

  19. 19.

    Krol, M., Papenburg, J., Tan, S.S., et al.: A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs. Eur J Health Econ. 17(4), 391–402 (2016)

    PubMed  Article  Google Scholar 

  20. 20.

    Krol, M., Papenburg, J., van Exel, J.: Does including informal care in economic evaluations matter? A systematic review of inclusion and impact of informal care in cost-effectiveness studies. Pharmacoeconomics. 33(2), 123–135 (2015)

    PubMed  Article  Google Scholar 

  21. 21.

    GBD 2015 Mortality and Causes of Death Collaborators: Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 388, 1459–1544 (2016)

    Article  Google Scholar 

  22. 22.

    GBD 2015 DALYs and HALE Collaborators: Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388, 1603–1658 (2016)

    Article  Google Scholar 

  23. 23.

    Alzheimer’s Association: 2017 Alzheimer’s disease facts and figures. Alzheimers Dement. 13(4), 325–373 (2017)

    Article  Google Scholar 

  24. 24.

    Costa, N., Ferlicoq, L., Derumeaux-Burel, H., Rapp, T., Garnault, V., Gillette-Guyonnet, S., Andrieu, S., Vellas, B., Lamure, M., Grand, A., Molinier, L.: Comparison of informal care time and costs in different age-related dementias: a review. Biomed. Res. Int. 2013, 852368 (2013)

    PubMed  Article  Google Scholar 

  25. 25.

    Mauskopf, J., Mucha, L.: A review of the methods used to estimate the cost of Alzheimer’s disease in the United States. Am. J. Alzheimers Dis. Other Demen. 26(4), 298–309 (2011)

    PubMed  Article  Google Scholar 

  26. 26.

    Cappell, J., Herrmann, N., Cornish, S., Lanctôt, K.L.: The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer’s disease. CNS Drugs 24(11), 909–927 (2010)

    PubMed  Article  Google Scholar 

  27. 27.

    Wimo, A., Guerchet, M., Ali, G.C., Wu, Y.T., Prina, A.M., Winblad, B., Jönsson, L., Liu, Z., Prince, M.: The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimers Dement. 13(1), 1–7 (2017)

    PubMed  PubMed Central  Article  Google Scholar 

  28. 28.

    López Bastida, J., Oliva Moreno, J., Serrano Aguilar, P., Perestelo, Pérez L.: The social economics costs and quality of life of Alzheimer disease in Spain. Neurology. 67(12), 2186–2191 (2006)

    PubMed  Article  Google Scholar 

  29. 29.

    Välimäki, T.H., Martikainen, J.A., Hongisto, K., Väätäinen, S., Sintonen, H., Koivisto, A.M.: Impact of Alzheimer’s disease on the family caregiver’s long-term quality of life: results from an ALSOVA followup study. Qual. Life Res. 25, 687–697 (2016)

    PubMed  Article  Google Scholar 

  30. 30.

    Bremer, P., Cabrera, E., Leino-Kilpi, H., Lethin, C., Saks, K., Sutcliffe, C.: Informal dementia care: consequences for caregivers’ health and health care use in 8 European countries. Health Policy 119, 1459–1471 (2015)

    PubMed  Article  Google Scholar 

  31. 31.

    Goren, A., Montgomery, W., Kahle-Wrobleski, K., Nakamura, T., Ueda, K.: Impact of caring for persons with Alzheimer’s disease or dementia on caregivers’ health outcomes: findings from a community based survey in Japan. BMC Geriatr. 16, 122 (2016)

    PubMed  PubMed Central  Article  Google Scholar 

  32. 32.

    Mareque, M., Oliva Moreno, J.: Social costs of diseases: how relevant are they for economic evaluations? Rev. Esp. Salud Publica. 22, 92. pii: e201808051 (2018)

  33. 33.

    Saret, C.J., Winn, A.N., Shah, G., Parsons, S.K., Lin, P.-J., Cohen, J.T., et al.: Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses. Blood 125(12), 1866–1869 (2015)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  34. 34.

    Center for the Evaluation of Value and Risk in Health. The Cost-Effectiveness Analysis Registry [Internet]. (Boston), Institute for Clinical Research and Health Policy Studies, Tufts Medical Center. www.cearegistry.org. Accessed 4 Feb 2018

  35. 35.

    OECD, Eurostat and World Health Organization: A system of health accounts 2011, Revised edn. OECD Publishing, Paris (2017)

    Google Scholar 

  36. 36.

    van den Berg, B., Brouwer, W.B., Koopmanschap, M.A.: Economic valuation of informal care. An overview of methods and applications. Eur. J. Health Econ. HEPAC Health Econ. Prev. Care. 5(1), 36–45 (2004)

    Article  Google Scholar 

  37. 37.

    Hoefman, R.J., van Exel, J., Brouwer, W.: How to include informal care in economic evaluations. PharmacoEconomics. 31(12), 1105–1119 (2013)

    PubMed  Article  Google Scholar 

  38. 38.

    Krol, M., Brouwer, W., Rutten, F.: Productivity costs in economic evaluations: past, present, future. Pharmacoeconomics. 31(7), 537–549 (2013). https://doi.org/10.1007/s40273-013-0056-3

    Article  PubMed  Google Scholar 

  39. 39.

    Goodrich, K., Kaambwa, B., Al-Janabi, H.: The inclusion of informal care in applied economic evaluation: a review. Value Health. 15(6), 975–981 (2012)

    PubMed  Article  Google Scholar 

  40. 40.

    Michaud, T.L., Kane, R.L., McCarten, J.R., Gaugler, J.E., Nyman, J.A., Kuntz, K.M.: Using cerebrospinal fluid biomarker testing to target treatment to patients with mild cognitive impairment: a cost-effectiveness analysis. PharmacoEconomics-Open. 2(3), 309–323 (2018)

    PubMed  Article  Google Scholar 

  41. 41.

    Lamb, S.E., Mistry, D., Alleyne, S., Atherton, N., Brown, D., Copsey, B., et al.: Aerobic and strength training exercise programme for cognitive impairment in people with mild to moderate dementia: the DAPA RCT. Health Technol. Assess. (Winchester, England) 22(28), 1–202 (2018)

    Article  Google Scholar 

  42. 42.

    Hornberger, J., Bae, J., Watson, I., Johnston, J., Happich, M.: Clinical and cost implications of amyloid beta detection with amyloid beta positron emission tomography imaging in early Alzheimer’s disease—the case of florbetapir. Curr. Med. Res. Opin. 33(4), 675–685 (2017)

    CAS  PubMed  Article  Google Scholar 

  43. 43.

    Tong, T., Thokala, P., McMillan, B., Ghosh, R., Brazier, J.: Cost effectiveness of using cognitive screening tests for detecting dementia and mild cognitive impairment in primary care. Int. J. Geriatr. Psychiatry 32(12), 1392–1400 (2017)

    PubMed  Article  Google Scholar 

  44. 44.

    Knapp, M., King, D., Romeo, R., Adams, J., Baldwin, A., Ballard, C., Banerjee, S., Barber, R., Bentham, P., Brown, R.G., Burns, A., Dening, T., Findlay, D., Holmes, C., Johnson, T., Jones, R., Katona, C., Lindesay, J., Macharouthu, A., McKeith, I., McShane, R., O’Brien, J.T., Phillips, P.P.J., Sheehan, B., Howard, R.: Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer’s disease (the DOMINO-AD trial). Int. J. Geriatr. Psychiatry 32(12), 1205–1216 (2017)

    PubMed  Article  Google Scholar 

  45. 45.

    Hornberger, J., Michalopoulos, S., Dai, M., Andrade, P., Dilla, T., Happich, M.: Cost-effectiveness of Florbetapir-PET in Alzheimer’s disease: a Spanish societal perspective. J. Ment. Health Policy Econ. 18(2), 63–73 (2015)

    PubMed  Google Scholar 

  46. 46.

    Saint-Laurent Thibault, C., Özer Stillman, I., Chen, S., Getsios, D., Proskorovsky, I., Hernandez, L., Dixit, S.: Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer’s type in the US. J. Med. Econ. 18(11), 930–943 (2015)

    PubMed  Article  Google Scholar 

  47. 47.

    D’Amico, F., Rehill, A., Knapp, M., Aguirre, E., Donovan, H., Hoare, Z., Hoe, J., Russell, I., Spector, A., Streater, A., Whitaker, C., Woods, R.T., Orrell, M.: Maintenance cognitive stimulation therapy: an economic evaluation within a randomized controlled trial. J. Am. Med. Dir. Assoc. 16(1), 63–70 (2015)

    PubMed  Article  Google Scholar 

  48. 48.

    Orgeta, V., Leung, P., Yates, L., Kang, S., Hoare, Z., Henderson, C., et al.: Individual cognitive stimulation therapy for dementia: a clinical effectiveness and cost-effectiveness pragmatic, multicentre, randomised controlled trial. Health Technol. Assess. (Winchester, England) 19(64), 1–108 (2015)

    Article  Google Scholar 

  49. 49.

    Touchon, J., Lachaine, J., Beauchemin, C., Granghaud, A., Rive, B., Bineau, S.: The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer’s disease to nursing homes: cost-effectiveness analysis in France. Eur. J. Health Econ. 15(8), 791–800 (2014)

    PubMed  Article  Google Scholar 

  50. 50.

    Sogaard, R., Sorensen, J., Waldorff, F.B., Eckermann, A., Buss, D.V., Phung, K.T., Waldemar, G.: Early psychosocial intervention in Alzheimer’s disease: cost utility evaluation alongside the Danish Alzheimer’s Intervention Study (DAISY). BMJ Open e004105 (2014)

  51. 51.

    Romeo, R., Knapp, M., Hellier, J., Dewey, M., Ballard, C., Baldwin, R., Bentham, P., Burns, A., Fox, C., Holmes, C., Katona, C., Lawton, C., Lindesay, J., Livingston, G., McCrae, N., Moniz-Cook, E., Murray, J., Nurock, S., O’Brien, J., Poppe, M., Thomas, A., Walwyn, R., Wilson, K., Banerjee, S.: Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. Br. J. Psychiatry 202(2), 121–128 (2013)

    PubMed  Article  Google Scholar 

  52. 52.

    Pfeil, A.M., Kressig, R.W., Szucs, T.D.: Alzheimer’s dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland. Swiss Med. Wkly 142, w13676 (2012)

    PubMed  Google Scholar 

  53. 53.

    Hartz, S., Getsios, D., Tao, S., Blume, S., Maclaine, G.: Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer’s disease in Germany using discrete event simulation. BMC Neurol. 12, 2 (2012)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  54. 54.

    Rive, B., Aarsland, D., Grishchenko, M., Cochran, J., Lamure, M., Toumi, M.: Cost-effectiveness of memantine in moderate and severe Alzheimer’s disease in Norway. Int. J. Geriatr. Psychiatry 27(6), 573–582 (2012)

    CAS  PubMed  Article  Google Scholar 

  55. 55.

    Getsios, D., Blume, S., Ishak, K.J., Maclaine, G., Hernández, L.: An economic evaluation of early assessment for Alzheimer’s disease in the United Kingdom. Alzheimers Dement. 8(1), 22–30 (2012)

    PubMed  Article  Google Scholar 

  56. 56.

    Guo, S., Getsios, D., Hernandez, L., Cho, K., Lawler, E., Altincatal, A., Lanes, S., Blankenburg, M.: Florbetaben PET in the early diagnosis of Alzheimer’s disease: a discrete event simulation to explore its potential value and key data gaps. Int J Alzheimers 548157 (2012)

  57. 57.

    Woods, R.T., Bruce, E., Edwards, R.T., Elvish, R., Hoare, Z., Hounsome, B., et al.: REMCARE: reminiscence groups for people with dementia and their family caregivers—effectiveness and cost-effectiveness pragmatic multicentre randomised trial. Health Technol. Assess. 16(48), v–xv, 1–116 (2012). https://doi.org/10.3310/hta16480

  58. 58.

    Lachaine, J., Beauchemin, C., Legault, M., Bineau, S.: Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease. Can. J. Psychiatry 56(10), 596–604 (2011)

    PubMed  Article  Google Scholar 

  59. 59.

    Nagy, B., Brennan, A., Brandtmüller, A., Thomas, S.K., Sullivan, S.D., Akehurst, R.: Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer’s disease in the UK using MMSE- and ADL-based models. Int. J. Geriatr. Psychiatry 26(5), 483–494 (2011)

    PubMed  Article  Google Scholar 

  60. 60.

    Getsios, D., Blume, S., Ishak, K.J., Maclaine, G.: Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer’s disease: a UK evaluation using discrete-event simulation. Pharmacoeconomics 28(5), 411–427 (2010)

    PubMed  Article  Google Scholar 

  61. 61.

    López-Bastida, J., Hart, W., García-Pérez, L., Linertová, R.: Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s disease. J. Alzheimers Dis. 16(2), 399–407 (2009)

    PubMed  Article  CAS  Google Scholar 

  62. 62.

    Wolfs, C.A., Dirksen, C.D., Kessels, A., Severens, J.L., Verhey, F.R.: Economic evaluation of an integrated diagnostic approach for psychogeriatric patients: results of a randomized controlled trial. Arch. Gen. Psychiatry 66(3), 313–323 (2009)

    PubMed  Article  Google Scholar 

  63. 63.

    Fuh, J.L., Wang, S.J.: Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer’s disease in Taiwan. Int. J. Geriatr. Psychiatry 23(1), 73–78 (2008)

    PubMed  Article  Google Scholar 

  64. 64.

    Kirbach, S., Simpson, K., Nietert, P.J., Mintzer, J.: A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer’s disease. Clin. Drug Investig 28(5), 291–303 (2008)

    PubMed  Article  Google Scholar 

  65. 65.

    Weycker, D., Taneja, C., Edelsberg, J., Erder, M.H., Schmitt, F.A., Setyawan, J., Oster, G.: Cost-effectiveness of memantine in moderate-to-severe Alzheimer’s disease patients receiving donepezil. Curr. Med. Res. Opin. 23(5), 1187–1197 (2007)

    CAS  PubMed  Article  Google Scholar 

  66. 66.

    McMahon, P.M., Araki, S.S., Neumann, P.J., Harris, G.J., Gazelle, G.S.: Cost-effectiveness of functional imaging tests in the diagnosis of Alzheimer disease. Radiology 217(1), 58–68 (2000)

    CAS  PubMed  Article  Google Scholar 

  67. 67.

    Reed, C., Happich, M., Argimon, J.M., Haro, J.M., Wimo, A., Bruno, G., Dodel, R., Jones, R.W., Vellas, B., Belger, M.: What drives country differences in cost of Alzheimer’s disease? an explanation from resource use in the GERAS study. J. Alzheimers Dis. 57(3), 797–812 (2017)

    PubMed  Article  Google Scholar 

  68. 68.

    Jönsson, L., Wimo, A.: The cost of dementia in Europe: a review of the evidence, and methodological considerations. Pharmacoeconomics. 27(5), 391–403 (2009)

    PubMed  Article  Google Scholar 

  69. 69.

    Chappell, N., Blandford, A.: Informal and formal care: exploring the complementarity. Ageing Soc. 11(03), 299–317 (1991)

    Article  Google Scholar 

  70. 70.

    Jimenez-Martin, S., Prieto, C.V.: The trade-off between formal and informal care in Spain. Eur. J. Health Econ. 13(4), 461–490 (2012)

    PubMed  Article  Google Scholar 

Download references

Funding

 This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779312.

Author information

Affiliations

Authors

Corresponding author

Correspondence to L. M. Peña-Longobardo.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Peña-Longobardo, L.M., Rodríguez-Sánchez, B., Oliva-Moreno, J. et al. How relevant are social costs in economic evaluations? The case of Alzheimer’s disease. Eur J Health Econ 20, 1207–1236 (2019). https://doi.org/10.1007/s10198-019-01087-6

Download citation

Keywords

  • Alzheimer’s disease
  • Economic evaluation
  • Labour productivity
  • Informal care
  • Societal perspective
  • Social costs
  • Cost–effectiveness
  • Cost–utility

JEL Classification

  • I11
  • I15
  • I18
  • H0